人源单克隆抗体作为针对新兴病毒和 HIV-1 的候选治疗药物。
Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.
机构信息
Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
出版信息
Virol Sin. 2013 Apr;28(2):71-80. doi: 10.1007/s12250-013-3313-x. Epub 2013 Apr 11.
Abstract
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis) - for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
摘要
已有超过 40 种单克隆抗体（mAbs）被批准用于多种疾病适应症，其中只有一种（Synagis）用于病毒疾病，不是用于治疗，而是用于预防。然而，在过去十年中，已经发现并表征了新型强效 mAbs，它们具有作为治疗剂对抗对公共卫生和生物安全具有重要意义的病毒的潜力，包括亨德拉病毒（HeV）、尼帕病毒（NiV）、严重急性呼吸综合征冠状病毒（SARS-CoV）、埃博拉病毒（EBOV）、西尼罗河病毒（WNV）、流感病毒（IFV）和人类免疫缺陷病毒 1 型（HIV-1）。在这里，我们重点介绍具有人类来源的抗体的此类 mAbs，并强调最近的结果以及与其作为治疗剂的潜力相关的技术和机制。
相似文献
1
Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.人源单克隆抗体作为针对新兴病毒和 HIV-1 的候选治疗药物。
Virol Sin. 2013 Apr;28(2):71-80. doi: 10.1007/s12250-013-3313-x. Epub 2013 Apr 11.
2
Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses.针对严重急性呼吸综合征冠状病毒、尼帕病毒和亨德拉病毒的强效人源单克隆抗体。
Expert Opin Biol Ther. 2009 Mar;9(3):355-68. doi: 10.1517/14712590902763755.
3
Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.强效亨德拉尼帕病毒中和抗体通过识别亨德拉和尼帕病毒受体结合蛋白上不同位点。
Cell. 2020 Dec 10;183(6):1536-1550.e17. doi: 10.1016/j.cell.2020.11.023.
4
Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.采用新型高通量筛选检测法鉴定广谱抗严重急性呼吸综合征冠状病毒和埃博拉、亨德拉及尼帕病毒的小分子抗病毒药物。
J Virol. 2014 Apr;88(8):4353-65. doi: 10.1128/JVI.03050-13. Epub 2014 Feb 5.
5
Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.人源单克隆抗体对亨德拉病毒和尼帕病毒的强效中和作用。
J Virol. 2006 Jan;80(2):891-9. doi: 10.1128/JVI.80.2.891-899.2006.
6
Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens.从人脐带血中鉴定种系抗体库并筛选针对病毒包膜糖蛋白的单克隆抗体：对免疫逃逸机制和疫苗免疫原设计的启示。
Biochem Biophys Res Commun. 2012 Jan 27;417(4):1164-9. doi: 10.1016/j.bbrc.2011.12.089. Epub 2011 Dec 27.
7
Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses.针对由新兴病毒和生物防御相关病毒引起的疾病的人源单克隆抗体的研发。
Expert Rev Anti Infect Ther. 2006 Feb;4(1):57-66. doi: 10.1586/14787210.4.1.57.
8
Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.急性亨德拉病毒感染：仓鼠模型中的发病机制及被动抗体保护分析
Virology. 2009 May 10;387(2):459-65. doi: 10.1016/j.virol.2009.03.001. Epub 2009 Mar 28.
9
Vaccines to Emerging Viruses: Nipah and Hendra.新兴病毒疫苗：尼帕病毒和亨德拉病毒。
Annu Rev Virol. 2020 Sep 29;7(1):447-473. doi: 10.1146/annurev-virology-021920-113833.
10
Pathogenesis of Hendra and Nipah virus infection in humans.亨德拉病毒和尼帕病毒感染人类的发病机制。
J Infect Dev Ctries. 2013 Apr 17;7(4):308-11. doi: 10.3855/jidc.3648.
引用本文的文献
1
Identification of potential therapeutic drugs targeting core genes for systemic lupus erythematosus (SLE) and coexisting COVID-19: Insights from bioinformatic analyses.基于生物信息学分析鉴定系统性红斑狼疮（SLE）合并新冠病毒（COVID-19）的核心基因治疗靶点的潜在药物
Immun Inflamm Dis. 2023 Nov;11(11):e1087. doi: 10.1002/iid3.1087.
2
A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022.基于 CR3022 产生的针对 SARS-CoV-2 奥密克戎变异株的中和双特异性单链抗体
Front Cell Infect Microbiol. 2023 May 3;13:1155293. doi: 10.3389/fcimb.2023.1155293. eCollection 2023.
3
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.鉴定针对 SARS-CoV-2 的有效人类中和抗体，对治疗和预防药物的开发具有重要意义。
Nat Commun. 2021 Aug 9;12(1):4887. doi: 10.1038/s41467-021-25153-x.
4
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.关于新型冠状病毒 SARS-CoV-2 的治疗性中和抗体的观点。
Int J Biol Sci. 2020 Mar 15;16(10):1718-1723. doi: 10.7150/ijbs.45123. eCollection 2020.
5
Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics.具有优化物理化学性质的Fc片段工程，意味着基于Fc的治疗药物临床潜力的提升。
Front Immunol. 2018 Jan 8;8:1860. doi: 10.3389/fimmu.2017.01860. eCollection 2017.
6
G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide DLVPR with high affinity.G196 表位标签系统：一种新型单克隆抗体 G196 能够高亲和力识别小的可溶性肽 DLVPR。
Sci Rep. 2017 Mar 7;7:43480. doi: 10.1038/srep43480.
7
Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.大多数中和性人源单克隆抗体针对需要拉沙病毒糖蛋白亚单位两者的新型表位。
Nat Commun. 2016 May 10;7:11544. doi: 10.1038/ncomms11544.
8
Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.人源单克隆抗体对中东呼吸综合征冠状病毒的超强中和作用。
J Virol. 2014 Jul;88(14):7796-805. doi: 10.1128/JVI.00912-14. Epub 2014 Apr 30.
9
A treatment for and vaccine against the deadly Hendra and Nipah viruses.亨德拉和尼帕病毒的治疗方法和疫苗。
Antiviral Res. 2013 Oct;100(1):8-13. doi: 10.1016/j.antiviral.2013.06.012. Epub 2013 Jul 6.
10
N-terminal truncation of an isolated human IgG1 CH2 domain significantly increases its stability and aggregation resistance.分离出的人IgG1 CH2结构域的N端截短显著提高了其稳定性和抗聚集性。
Mol Pharm. 2013 Jul 1;10(7):2642-52. doi: 10.1021/mp400075f. Epub 2013 May 29.
本文引用的文献
1
Broadly neutralizing antibodies against HIV-1: templates for a vaccine.广谱中和抗体抗 HIV-1：疫苗的模板。
Virology. 2013 Jan 5;435(1):46-56. doi: 10.1016/j.virol.2012.10.004.
2
Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.针对 SARS-CoV 刺突蛋白高度保守的 HR1 和 HR2 结构域的人源单克隆抗体具有更广泛的中和作用。
PLoS One. 2012;7(11):e50366. doi: 10.1371/journal.pone.0050366. Epub 2012 Nov 21.
3
Potential vaccines and post-exposure treatments for filovirus infections.丝状病毒感染的潜在疫苗和暴露后治疗方法。
Viruses. 2012 Sep;4(9):1619-50. doi: 10.3390/v4091619. Epub 2012 Sep 21.
4
Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans.人类急性呼吸窘迫综合征相关新发现冠状病毒的基因组特征。
mBio. 2012 Nov 20;3(6):e00473-12. doi: 10.1128/mBio.00473-12.
5
Use of human monoclonal antibodies to treat Chikungunya virus infection.利用人源单克隆抗体治疗基孔肯雅热病毒感染。
J Infect Dis. 2013 Jan 15;207(2):319-22. doi: 10.1093/infdis/jis674. Epub 2012 Nov 2.
6
Characterization of human IgG repertoires in an acute HIV-1 infection.急性 HIV-1 感染中人类 IgG 库的特征分析。
Exp Mol Pathol. 2012 Dec;93(3):399-407. doi: 10.1016/j.yexmp.2012.09.022. Epub 2012 Oct 1.
7
Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.非中和抗体抑制马尔堡病毒包膜糖蛋白出芽。
J Virol. 2012 Dec;86(24):13467-74. doi: 10.1128/JVI.01896-12. Epub 2012 Oct 3.
8
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.人源中和 HIV-1 的抗体：鉴定、结构和 B 细胞发生。
Immunity. 2012 Sep 21;37(3):412-25. doi: 10.1016/j.immuni.2012.08.012.
9
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.HIV-1 抗体：感染与疫苗接种的启示，有助于指导疫苗设计。
Trends Microbiol. 2012 Nov;20(11):532-9. doi: 10.1016/j.tim.2012.08.011. Epub 2012 Sep 13.
10
Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.双特异性工程抗体结构域（纳米抗体）与 HIV-1 中和表位和 FcRn 非竞争性相互作用。
PLoS One. 2012;7(8):e42288. doi: 10.1371/journal.pone.0042288. Epub 2012 Aug 7.
Zotero 插件